147 related articles for article (PubMed ID: 36672308)
1. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Hamada T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672308
[TBL] [Abstract][Full Text] [Related]
2. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A
Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Aug; 51(9):1416-1422. PubMed ID: 34128055
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
8. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
9. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.
Mita N; Iwashita T; Uemura S; Yoshida K; Iwasa Y; Ando N; Iwata K; Okuno M; Mukai T; Shimizu M
J Clin Med; 2019 May; 8(6):. PubMed ID: 31146420
[TBL] [Abstract][Full Text] [Related]
10. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract][Full Text] [Related]
12. Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer.
Sadaka S; Iwashita T; Fujii H; Kato-Hayashi H; Ohata K; Uemura S; Shimizu M; Suzuki A
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233762
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
[TBL] [Abstract][Full Text] [Related]
14. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.
Quan Q; Wang Y; Wang F; Zhang D; Chen X; He W; Zhang B; Guo G
Curr Oncol; 2020 Dec; 28(1):209-219. PubMed ID: 33704188
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Kan M; Imaoka H; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Umemoto K; Kimura G; Suzuki Y; Eguchi H; Otsuru T; Goda K; Ikeda M
Cancer Chemother Pharmacol; 2020 Aug; 86(2):203-210. PubMed ID: 32632515
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Chan KKW; Guo H; Cheng S; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM; Mittmann N; Coburn N; Arias J; Schwartz D; Dai WF; Gavura S; McLeod R; Kennedy ED
Cancer Med; 2020 Jan; 9(1):160-169. PubMed ID: 31724340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
